Richard Saynor, CEO of Sandoz Group AG, aims to position the company as a leader in producing generic versions of cutting-edge drugs, including anti-obesity treatments. He highlights the significant market opportunity as many drugs come off patent, but raises concerns about the environmental impact of mass-producing these medications, particularly regarding waste from vials. Saynor emphasizes the need for sustainable solutions in the pharmaceutical industry as demand for these drugs grows.
